These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 19730864

  • 1. Progressive multiple sclerosis.
    Bradl M, Lassmann H.
    Semin Immunopathol; 2009 Nov; 31(4):455-65. PubMed ID: 19730864
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Progressive multiple sclerosis: pathology and pathogenesis.
    Lassmann H, van Horssen J, Mahad D.
    Nat Rev Neurol; 2012 Nov 05; 8(11):647-56. PubMed ID: 23007702
    [Abstract] [Full Text] [Related]

  • 5. Overexpression of the ubiquitin-editing enzyme A20 in the brain lesions of Multiple Sclerosis patients: moving from systemic to central nervous system inflammation.
    Perga S, Montarolo F, Martire S, Bonaldo B, Bono G, Bertolo J, Magliozzi R, Bertolotto A.
    Brain Pathol; 2021 Mar 05; 31(2):283-296. PubMed ID: 33051914
    [Abstract] [Full Text] [Related]

  • 6. Neuropathologic, phenotypic and functional analyses of Mucosal Associated Invariant T cells in Multiple Sclerosis.
    Salou M, Nicol B, Garcia A, Baron D, Michel L, Elong-Ngono A, Hulin P, Nedellec S, Jacq-Foucher M, Le Frère F, Jousset N, Bourreille A, Wiertlewski S, Soulillou JP, Brouard S, Nicot AB, Degauque N, Laplaud DA.
    Clin Immunol; 2016 May 05; 166-167():1-11. PubMed ID: 27050759
    [Abstract] [Full Text] [Related]

  • 7. Molecular signature of slowly expanding lesions in progressive multiple sclerosis.
    Jäckle K, Zeis T, Schaeren-Wiemers N, Junker A, van der Meer F, Kramann N, Stadelmann C, Brück W.
    Brain; 2020 Jul 01; 143(7):2073-2088. PubMed ID: 32577755
    [Abstract] [Full Text] [Related]

  • 8. [New therapeutic approaches in progressive multiple sclerosis].
    Faissner S, Gold R.
    Fortschr Neurol Psychiatr; 2019 Nov 01; 87(11):653-671. PubMed ID: 31783427
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis.
    Raveney BJE, Sato W, Takewaki D, Zhang C, Kanazawa T, Lin Y, Okamoto T, Araki M, Kimura Y, Sato N, Sano T, Saito Y, Oki S, Yamamura T.
    Proc Natl Acad Sci U S A; 2021 Mar 16; 118(11):. PubMed ID: 33836594
    [Abstract] [Full Text] [Related]

  • 11. The relation between inflammation and neurodegeneration in multiple sclerosis brains.
    Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H.
    Brain; 2009 May 16; 132(Pt 5):1175-89. PubMed ID: 19339255
    [Abstract] [Full Text] [Related]

  • 12. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
    Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F.
    Brain; 2007 Apr 16; 130(Pt 4):1089-104. PubMed ID: 17438020
    [Abstract] [Full Text] [Related]

  • 13. A new focal model resembling features of cortical pathology of the progressive forms of multiple sclerosis: Influence of innate immunity.
    Silva BA, Leal MC, Farías MI, Avalos JC, Besada CH, Pitossi FJ, Ferrari CC.
    Brain Behav Immun; 2018 Mar 16; 69():515-531. PubMed ID: 29378262
    [Abstract] [Full Text] [Related]

  • 14. Targets of therapy in progressive MS.
    Lassmann H.
    Mult Scler; 2017 Oct 16; 23(12):1593-1599. PubMed ID: 29041864
    [Abstract] [Full Text] [Related]

  • 15. A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode.
    Tutuncu M, Demirci NO, Özer F, Saip S, Kantarci OH, Siva A.
    Mult Scler; 2011 Oct 16; 17(10):1262-4. PubMed ID: 21135019
    [Abstract] [Full Text] [Related]

  • 16. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Choi IY, Lee P, Adany P, Hughes AJ, Belliston S, Denney DR, Lynch SG.
    Mult Scler; 2018 Jul 16; 24(8):1029-1038. PubMed ID: 28569645
    [Abstract] [Full Text] [Related]

  • 17. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke.
    Lopes Pinheiro MA, Kooij G, Mizee MR, Kamermans A, Enzmann G, Lyck R, Schwaninger M, Engelhardt B, de Vries HE.
    Biochim Biophys Acta; 2016 Mar 16; 1862(3):461-71. PubMed ID: 26527183
    [Abstract] [Full Text] [Related]

  • 18. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J, Börnsen L, Khademi M, Olsson T, Jensen PE, Sørensen PS, Sellebjerg F.
    Mult Scler; 2013 Jun 16; 19(7):877-84. PubMed ID: 23178691
    [Abstract] [Full Text] [Related]

  • 19. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C, Battaglini M, Stromillo ML, Bartolozzi ML, Guidi L, Federico A, De Stefano N.
    Arch Neurol; 2008 Feb 16; 65(2):236-43. PubMed ID: 18268194
    [Abstract] [Full Text] [Related]

  • 20. Targeting Mitochondrial Metabolism in Neuroinflammation: Towards a Therapy for Progressive Multiple Sclerosis.
    Peruzzotti-Jametti L, Pluchino S.
    Trends Mol Med; 2018 Oct 16; 24(10):838-855. PubMed ID: 30100517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.